phrykt

Bright Minds Biosciences Inc. (DRUG): who owns it and who trades it

As of Nov 16, 2026, DRUG insiders reported 1 open-market sale worth $9.8M and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Cormorant Asset Management, LP (Other), with $9.8M. 4 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Bright Minds Biosciences

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Funds mostly bought. Famous investors was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns DRUG

100 funds and institutions reported DRUG shares worth $655M at the end of Q2 2026. The largest holder is Jupiter Topco LLC with $94.8M.

10 largest owners, by value

Jupiter Topco LLC$94.8M
Cormorant Asset Management, LP$63.2M
BlackRock, Inc.$48.2M
Vivo Capital, LLC$39.1M
Vestal Point Capital, LP$38.3M
Braidwell LP$34M
Driehaus Capital Management LLC$30.4M
Balyasny Asset Management L.P.$24.2M
Adage Capital Partners Gp, L.l.c.$23.5M
Point72 Asset Management, L.P.$23M

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Jupiter Topco LLC1.35M–$94.8MNew
Cormorant Asset Management, LP900,000–$63.2M-15%
BlackRock, Inc.686,184–$48.2M+10%
Vivo Capital, LLC557,172–$39.1MNo change
Vestal Point Capital, LP545,000–$38.3M+11%
Braidwell LP483,822–$34M-10%
Driehaus Capital Management LLC433,377–$30.4M+0%
Balyasny Asset Management L.P.345,053–$24.2M+16%
Adage Capital Partners Gp, L.l.c.335,000–$23.5M-32%
Point72 Asset Management, L.P.327,416–$23MNew
Deerfield Management Company, L.P.283,000–$19.9MNo change
Ra Capital Management, L.P.265,000–$18.6MNo change
Parkman Healthcare Partners LLC205,053–$14.4M+411%
Mpm Bioimpact LLC202,114–$14.2M-5%
Wellington Management Group LLP171,315–$12M+25%
Goldman Sachs Group Inc133,689–$9.4M+80%
Eventide Asset Management, LLC130,013–$9.1MNo change
State Street Corp122,178–$8.6M+13%
Seven Grand Managers, LLC120,000–$8.4MNo change
Great Point Partners LLC109,603–$7.7M-50%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, DRUG insiders reported $0 of open-market purchases and $9.8M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$9.8M
1 trades, 1 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Apr 28, 2026
Filed Apr 30, 2026

Purchases and sales by month

$9.8M$9.8MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Apr 28, 2026Cormorant Asset Management, LP +2OtherSale109,331$89.50$9.8MForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Cormorant Asset Management, LPOther–$9.8MApr 28, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

DRUG short interest

801,241 DRUG shares are sold short. Over the last 12 reports the number of shares short went up 6%.

As of Oct 30, 2026, 801,241 DRUG shares were sold short, down 3.4% from the report before. At the average daily volume of 101,302 shares, buying them all back would take about 7.9 trading days (days to cover).

Shares short

801,241May 15Oct 30985,703

Days to cover

7.9May 15Oct 3013.6

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 2026801,241–-3%101,3027.9
Oct 15, 2026829,718–-6%184,2114.5
Sep 30, 2026882,832–-5%104,4048.5
Sep 15, 2026931,941–+4%77,68312.0
Aug 31, 2026893,571–-0%126,4977.1
Aug 14, 2026897,280–+1%165,4805.4
Jul 31, 2026890,847–-7%220,0764.0
Jul 15, 2026955,805–+0%311,4943.1
Jun 30, 2026952,509–+16%264,3803.6
Jun 15, 2026817,654–+1%610,5981.3
May 29, 2026805,672–+7%279,7072.9
May 15, 2026756,484–+1%205,4353.7

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Famous investors that hold DRUG

4 of the 50 well-known investors we track reported holding DRUG in their latest 13F filing. The largest position is Steve Cohen's, worth $18.6M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Steve Cohen · Point72 Asset ManagementQ3 2026372,481$18.6M0.0%+14%
Israel Englander · Millennium ManagementQ3 202688,640$4.4M0.0%+33%
Ken Griffin · Citadel AdvisorsQ3 202654,116$2.7M0.0%-19%
Paul Tudor Jones · Tudor Investment CorpQ3 20268,241$411K0.0%-1%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named DRUG in the last 120 days.

FiledHolderFormStake
Nov 16, 2026Cormorant Asset Management, LP13G/A8.1%
Nov 16, 2026Vivo Opportunity Fund Holdings, L.P.13G/A3.8%
Nov 16, 2026Cormorant Asset Management, LP13G/A8.1%
Nov 16, 2026Vivo Opportunity Fund Holdings, L.P.13G/A3.8%

Questions about Bright Minds Biosciences Inc. (DRUG) stock

Who owns the most DRUG stock?

The largest reported owner of Bright Minds Biosciences Inc. (DRUG) is Jupiter Topco LLC. In total, 100 funds and institutions reported holding DRUG at the end of Q2 2026. See the largest owners.

Are DRUG insiders buying or selling?

In the last 12 months, DRUG insiders reported no open-market purchases and 1 sale worth $9.8M. The latest trade was on Apr 28, 2026. See every trade.

What is the short interest in DRUG?

As of Oct 30, 2026, 801,241 DRUG shares were sold short, down 3.4% from the report before. At the average daily volume of 101,302 shares, buying them all back would take about 7.9 trading days (days to cover). See the history.

Which famous investors hold DRUG?

4 of the 50 well-known investors we track reported DRUG in their latest 13F filing, including Steve Cohen, Israel Englander, Ken Griffin. The largest position is worth $18.6M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.